Topical Collection "Targeting Cell Metabolism as Cancer Therapy"

Editor

Dr. Veronique Baud
E-Mail Website
Guest Editor
1. "NF-kB, Differenciation and Cancer", University Paris Descartes, Sorbonne Paris Cité, 75014 Paris, France
2. Faculté de Pharmacie, 4 Avenue de l'Observatoire, 75006 Paris, France
Interests: interface between signal transduction and cancer with a focus on the alternative NF-kappaB signaling pathway, how it is regulated, and its contributions towards tumor development and resistance to conventional cancer therapies
Special Issues, Collections and Topics in MDPI journals

Topical Collection Information

Dear Colleagues,

Reprogramming of energy metabolism in cancer has recently been recognized as one of the hallmarks of cancer and its understanding will contribute to the development of new anticancer strategies and/or improve the effectiveness of existing therapies.

This Topical Collection aims to publish research on the metabolic features of solid and hematological cancers, including cancer cells and the tumor microenvironment, and how to exploit the metabolic perturbations to develop new anticancer treatments.

We invite research and review papers covering all aspects of cancer cell metabolism and related innovative cancer therapies. Topics include, but are not limited to, fundamental understanding of metabolic disturbance in cancer, associated gene expression profiling, epigenetic regulation, metabolomics, diagnostic and prognostic biomarkers, molecular targets, cancer drug development targeting metabolism, clinical trials with new agents, and validation in animal models.

Dr. Veronique Baud
Collection Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Reprogramming of metabolic pathways in cancer cells
  • Deciphering metabolic signaling pathways
  • Cancer metabolism related to:
    • gene expression profiling
    • metabolomics
    • epigenetics
    • oncogenomics
    • biomarkers
    • cancer targeted diagnosis
    • cancer-targeted therapeutics
    • innovative anti-metabolic therapies
    • mechanism-based drug development
    • drug discovery
    • clinical trials
    • animal models

 

Published Papers (1 paper)

2021

Article
Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling
Biomedicines 2021, 9(12), 1759; https://doi.org/10.3390/biomedicines9121759 - 24 Nov 2021
Cited by 1 | Viewed by 298
Abstract
Langerhans cell histiocytosis (LCH) is a rare disease that has a variable clinical presentation and unpredictable behavior. Until recently, therapeutic options were limited. Insights into the role of mitogen-activated protein kinase (MAPK) signaling have allowed the increased use of targeted treatments. Before the [...] Read more.
Langerhans cell histiocytosis (LCH) is a rare disease that has a variable clinical presentation and unpredictable behavior. Until recently, therapeutic options were limited. Insights into the role of mitogen-activated protein kinase (MAPK) signaling have allowed the increased use of targeted treatments. Before the advent of drugs that interfere with this pathway, investigations concerning the tyrosine kinase inhibitor imatinib opened the way to a rationale-based therapeutic approach to the disease. Imatinib block the binding site of ATP in the BCR/ABL protein and is also a platelet-derived growth factor receptor (PDGFR) and a KIT (CD117) kinase inhibitor. A case of refractory LCH with brain involvement was reported to be successfully treated with imatinib. Thereafter, we further explored the role of this tyrosine kinase inhibitor. The present study is composed of an immunohistochemical evaluation of PDGFRβ expression and a clinical evaluation of imatinib in a series of LCH patients. In the first part, a series of 10 samples obtained from LCH patients was examined and a strong immunohistochemistry expression of PDGFRβ was found in 40% of the cases. In the clinical part of the study, five patients were enrolled. Long-lasting disease control was obtained. These results may suggest a potential role for this drug in the current age. Full article
Show Figures

Graphical abstract

Back to TopTop